Abstract:Biological activities of 29 novel quinazoline/phenylsulfonylfuroxan derivatives were in silico investigated as potential anticancer inhibitors against five cell lines, i.e., H1975, MCF‐7, Eca‐109, MGC‐803, and A549, which are involved in lung, breast, esophageal squamous carcinoma, and gastric cancer diseases. The combining QSAR predictive approach, molecular docking, and dynamics simulations allow the design of 70 new hybrids and predict their pIC50 activity. In this work, the biological activities of 29 novel quinazoline/phenylsulfonylfuroxan derivatives (1a–z, 1aa, 1ab, 2a, 2b, 2d, and 2f) were computationally investigated as potential anti‐cancer inhibitors against five cell lines, i.e., H1975, MCF‐7, Eca‐109, MGC‐803, and A549, which are involved in various diseases, including lung, breast, esophageal squamous carcinoma, and gastric cancer. The 2D‐QSAR predictive approach, exploiting multiple linear regression (MLR) models and rigorous internal and external cross‐validation, showed a correlation factor R2 of range: 0.68−0.82. Moreover, the MLR‐derived R2test and Y randomization (R2rand) values for the five cell lines are higher than 0.60 and less than 0.3, respectively, indicating a strong alignment with the internal and external validation data. New 70 quinazoline hybrids based on the most effective in vivo 1q inhibitor were designed, and their pIC50 activity was predicted. The best‐scoring 15 (N1–N15) compounds were further evaluated using molecular docking and dynamics simulations (100 ns) with the VEGFR‐2 kinase target (PDB code: 3U6J). All the data sets accurately predict the strongest binding affinity for the selected (N6, N7, N9, and N11) molecules, as evidenced by the highest docking score, hydrogen bond energy, and significant amino acid steric interactions. Furthermore, the RMS/RMSF/Rg dynamics parameters show that the formed complexes are satisfactorily stable. The ADMET properties indicate that the selected new ligands have shown a promising drug‐like profile and can be considered potential candidates for future anti‐cancer therapies, with perspective validating their anticancer activity by in vitro and in vivo studies.

Design, synthesis and biological evaluation of novel quinazoline derivatives as immune checkpoint inhibitors

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Synthesis, Molecular Modeling, and Biological Evaluation of Quinazoline Derivatives Containing the 1,3,4-Oxadiazole Scaffold As Novel Inhibitors of VEGFR2

New Application of Novel Tetrazine Derivatives As Potent VEGFR-2 Kinase Inhibitors and Anti-Cancer Agents

Synthesis and Biological Evaluation of Quinoline–imidazole Hybrids As Potent Telomerase Inhibitors: a Promising Class of Antitumor Agents

Synthesis and biological evaluation of novel podophyllotoxin analogs as antitumor agents.

Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives As Novel Inhibitors of VEGFR2.

Novel quinazolines bearing 1,3,4-thiadiazole-aryl urea derivative as anticancer agents: design, synthesis, molecular docking, DFT and bioactivity evaluations

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors.

Synthesis, Molecular Modeling and Biological Evaluation of 2-Aminomethyl-5-(quinolin-2-yl)-1,3,4-oxadiazole-2(3h)-thione Quinolone Derivatives As Novel Anticancer Agent

Design, synthesis, and evaluation of novel (E)-N'-(3-allyl-2-hydroxy)benzylidene-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides as antitumor agents

Syntheses and Cytotoxicities of Quinazolinone-Based Conjugates

Design, Synthesis, and Molecular Docking Studies of New Quinoline-Thiazole Hybrids, Potential Leads in the Development of Novel Antileukemic Agents

Novel Penta-1,4-Diene-3-One Derivatives Containing Quinazoline And Oxime Ether Fragments: Design, Synthesis And Bioactivity

Design, Synthesis, and Activity Evaluation of Novel Dual-Target Inhibitors with Antifungal and Immunoregulatory Properties

Synthesis and evaluation of a novel series of quinoline derivatives with immunosuppressive activity.

New Quinazolinone‐Thiouracil Derivatives: Design, Synthesis, Anticancer Evaluation, and In Silico Analysis

Novel quinoline-4-carboxamide derivatives potentiates apoptosis by targeting PDK1 to overcome chemo-resistance in colorectal cancer: Theoretical and experimental results

Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study

Unveiling Novel Hybrids Quinazoline/Phenylsulfonylfuroxan Derivatives with Potent Multi‐Anticancer Inhibition: DFT and In Silico Approach Combining 2D‐QSAR, Molecular Docking, Dynamics Simulations, and ADMET Properties